AdOM Advanced Optical Methods Overview
AdOM Advanced Optical Methods specializes in two primary areas: optical imaging capabilities and clinical and research ophthalmology skills. AdOM develops thin-film optical imaging technologies to master the spectral imaging domain for clinical ophthalmology. The company is currently focused on the commercialization of its Tear Film Imager (TFI), which measures clinically relevant parameters of the tear film dynamics. The TFI uses spectral interference to image the corneal surface with a large field of view and high lateral resolution.
Cumulative Funding Raised Over Time ($)
$1.0MMay 2022
Latest News
Growth-Positive
The Short-term Effects of Artificial Tears on the Tear Film ... : Cornea
A study was conducted to investigate the effects of artificial tears on the sublayers of the tear film using a novel tear film imaging (TFI) device developed by AdOM, an Israel-based company. The study involved 11 healthy participants, 9 of whom had meibomian gland disease. The results showed that a substantial acute mean MALT increase occurs 1 minute after artificial tear instillation with all agents tested, but there were clear differences in response and durability. The study was supported in part by the Marrus Family Foundation, the Geraldine Violett Foundation, and a Challenge Grant from Research to Prevent Blindness.
Customers
growth-positive
Study: Prototype imager of tear film sublayers opens eyes on dry eye
Researchers have developed a noninvasive tear film imager that can provide accurate information on the stability of the tear film and its sublayers. The imager, although still a prototype, offers dynamic mapping of the tear film and can provide quantified information about its various attributes. This technology could be valuable for eye doctors in diagnosing and understanding dry eye. The practicality and ease of use of the imager will be important for its widespread implementation in optometry.
Customers
growth-positive
המכשיר החדשני שיזהה חולי קורונה בצילום עיניים - וב-40 שניות חדשות 13
Israeli company, אדום, has developed a groundbreaking device that can detect the COVID-19 virus by imaging the layers of the eye. The device, which is the first of its kind, uses eye imaging to identify the virus envelope. The device has shown promising results in initial feasibility studies, with 10 out of 10 infected individuals showing signs of the virus in their tears. Further research and testing are needed to validate the devices effectiveness on a larger scale. The potential impact of the device is significant, but it will require additional funding and time to expand the research and include a larger sample size.
Customers
growth-positive
COVID Eye Detection Study at Sheba Hospital the Tear Film Imager (TFI) 40 Second Eye Exam Achieves 91% Sensitivity in Diagnosing COVID-19 vs PCR Standard of Care
AdOM Advanced Optical Technologies concluded a head-to-head prospective trial of the TFI vs PCR in COVID-19 patients, showing 91% sensitivity compared to the existing PCR standard of care. The study used a device called Tear Film Imager (TFI) and demonstrated excellent results in detecting COVID-19. AdOM also announced that an abstract about the use of the TFI for COVID-19 detection has been accepted for presentation at the 2022 ARVO Annual Meeting. The TFI is a non-invasive medical device that measures all sublayers of the tear film and has the ability to detect viruses within the tear film at nanometer resolution. The company is seeking regulatory authorization in other territories.
PartnersCustomers
growth-positive
AdOM והמרכז הרפואי שיבא משיקים מחקר פורץ דרך לאיתור קוביד-19 בלומר
AdOM Advanced Optical Technologies LTD is partnering with Sheba Medical Center to conduct one of the worlds largest studies to determine if their Tar Film Imager (TFI) can effectively diagnose COVID-19 through a quick, non-invasive assessment of tear film in the eye. The research will compare the use of TFI against the current standard of PCR testing. The first patient has already been registered and the study will be conducted over the next 30 days, with an expectation to recruit about 500 patients.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $1M |
| Last funding | $1M |
| Stage | A |
| Rounds | 1 |
| Investors | 0 |
Team Members
6
Employees: 11-50
Web & Social Links
| Website | www.tearfilmimager.com |
Locations
HaMelacha Street 1, Lod, Israel
Photos & Videos
1 item(s)
AdOM Advanced Optical Methods Business
Business models
B2B
Product stage
Beta
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesDigital HealthcareDigital Medical DiagnosticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Semiconductors & ElectronicsDigital Signal ProcessorArtificial IntelligenceTags (12)
healthcare-providershospitalsdiagnosticsmedical-technologiesophthalmologyalgorithmsdoctorsdigital-healthcareimage-processingmedical-deviceseye-diseasessignal-processingGeographic Markets
EuropeJapanCanadaIsraelNorth AmericaChinaAdOM Advanced Optical Methods Financials
$1M
Total funding
Undisclosed
Capital raised
$1M
Last funding
A
Funding stage
1
Total rounds
0
Investors
Cumulative Funding Raised Over Time ($)
$1.0MMay 2022
Private Equity Funding
A Round
May 2022
$1M
AdOM Advanced Optical Methods Lifecycle
Cumulative Funding Raised Over Time
$1.0MMay 2022
All Events
A Round
May 2022
$1M
AdOM Advanced Optical Methods News
8 articles
Growth-Positive
The Short-term Effects of Artificial Tears on the Tear Film ... : Cornea
A study was conducted to investigate the effects of artificial tears on the sublayers of the tear film using a novel tear film imaging (TFI) device developed by AdOM, an Israel-based company. The study involved 11 healthy participants, 9 of whom had meibomian gland disease. The results showed that a substantial acute mean MALT increase occurs 1 minute after artificial tear instillation with all agents tested, but there were clear differences in response and durability. The study was supported in part by the Marrus Family Foundation, the Geraldine Violett Foundation, and a Challenge Grant from Research to Prevent Blindness.
Customers
growth-positive
Study: Prototype imager of tear film sublayers opens eyes on dry eye
Researchers have developed a noninvasive tear film imager that can provide accurate information on the stability of the tear film and its sublayers. The imager, although still a prototype, offers dynamic mapping of the tear film and can provide quantified information about its various attributes. This technology could be valuable for eye doctors in diagnosing and understanding dry eye. The practicality and ease of use of the imager will be important for its widespread implementation in optometry.
Customers
growth-positive
המכשיר החדשני שיזהה חולי קורונה בצילום עיניים - וב-40 שניות חדשות 13
Israeli company, אדום, has developed a groundbreaking device that can detect the COVID-19 virus by imaging the layers of the eye. The device, which is the first of its kind, uses eye imaging to identify the virus envelope. The device has shown promising results in initial feasibility studies, with 10 out of 10 infected individuals showing signs of the virus in their tears. Further research and testing are needed to validate the devices effectiveness on a larger scale. The potential impact of the device is significant, but it will require additional funding and time to expand the research and include a larger sample size.
Customers
growth-positive
COVID Eye Detection Study at Sheba Hospital the Tear Film Imager (TFI) 40 Second Eye Exam Achieves 91% Sensitivity in Diagnosing COVID-19 vs PCR Standard of Care
AdOM Advanced Optical Technologies concluded a head-to-head prospective trial of the TFI vs PCR in COVID-19 patients, showing 91% sensitivity compared to the existing PCR standard of care. The study used a device called Tear Film Imager (TFI) and demonstrated excellent results in detecting COVID-19. AdOM also announced that an abstract about the use of the TFI for COVID-19 detection has been accepted for presentation at the 2022 ARVO Annual Meeting. The TFI is a non-invasive medical device that measures all sublayers of the tear film and has the ability to detect viruses within the tear film at nanometer resolution. The company is seeking regulatory authorization in other territories.
PartnersCustomers
growth-positive
AdOM והמרכז הרפואי שיבא משיקים מחקר פורץ דרך לאיתור קוביד-19 בלומר
AdOM Advanced Optical Technologies LTD is partnering with Sheba Medical Center to conduct one of the worlds largest studies to determine if their Tar Film Imager (TFI) can effectively diagnose COVID-19 through a quick, non-invasive assessment of tear film in the eye. The research will compare the use of TFI against the current standard of PCR testing. The first patient has already been registered and the study will be conducted over the next 30 days, with an expectation to recruit about 500 patients.
Partners
growth-positive
AdOM & Sheba Medical Center Launch Ground-Breaking Study to Detect COVID-19 By Non-Invasive Eye Exam
AdOM Advanced Optical Technologies has partnered with Sheba Medical Center to conduct a large study on the detection of COVID-19 through the tear film of the eye using the Tear Film Imager (TFI). The study aims to determine if the TFI device can effectively diagnose and determine COVID-19 status in a fast, affordable, noninvasive manner. The TFI device is designed to measure the muco-aqueous and lipid sublayers of the tear film and has already proven to identify a virus within the surface of the eye. The study will compare the TFI to the current standard of care, PCR diagnostic testing. The first patient has been enrolled, and the study is expected to enroll about 500 patients over the next 30 days.
PartnersCustomers
growth-positive
Optical Imager Could Help Diagnose, Treat Dry Eye Disease
AdOM Advanced Optical Methods Ltd. has developed a noninvasive optical imaging system called the Tear Film Imager, which can improve the diagnosis and treatment of dry eye disease. The device uses spectral measurements to accurately measure the tear film inner layers, including the aqueous sublayer. It has been used in clinical studies for dry eye diagnosis and treatment evaluation. The Tear Film Imager is the first device that can be used in ophthalmology or optometry settings to image the tear film and distinguish its inner layers with nanometer resolution.
CustomersPartners
growth-positive
Optical imager poised to improve diagnosis and treatment of dry eye disease
Researchers have developed a new non-invasive optical imaging system called the Tear Film Imager that improves diagnosis and treatments for dry eye disease. The device can be used in ophthalmology or optometry settings to image the tear film and distinguish its inner layers with nanometer resolution. The Tear Film Imager uses an eye-safe halogen light to illuminate the eye and analyzes the full spectrum of light reflection to accurately measure the tear film inner layers. The device has been used in two clinical studies and has the potential to inform better dry eye treatments, improve surgical outcomes, and lead to more accurate fitting of contact lenses.
Customers
AdOM Advanced Optical Methods Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 14 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
AdOM Advanced Optical Methods Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 98/100 |
| Missing | markets |
| BI Verification | Yotam Maman |
| Registrar ID | 514113133 |
| Crunchbase | adom-advanced-optical-technologies |
| Phone | +97286636786 |
| Creator | Maor Perlov |
| Creator email | maorperlov@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-10-13T00:00:00.000Z |
| Created | 2019-08-26T00:00:00.000Z |
| Claimed | Yes |